文献速递造血干细胞移植与细胞治疗

原发性免疫缺陷病的基因治疗

Gene therapy for primary immunodeficiencies.
PubMed 文献 · Br J Haematol · 2020-12-18

本文综述了原发性免疫缺陷病(PID)的造血干细胞基因治疗(HSC GT)发展。PID需根治性治疗,异基因造血干细胞移植(alloHSCT)存在移植物失败和移植物抗宿主病(GvHD)风险。自体HSC GT可避免这些并发症,首个获批产品用于腺苷脱氨酶缺乏性重症联合免疫缺陷(ADA-SCID)。新型基因编辑技术有望克服病毒基因添加的问题,但每种疾病需独特方法,且存在插入突变和脱靶毒性风险。

要点

  • 自体HSC GT可纠正造血谱系基因缺陷,避免alloHSCT的GvHD和移植物失败风险。
  • 首个获批HSC-GT产品用于ADA-SCID,标志该领域临床转化取得进展。
  • 基因编辑技术有望减少病毒基因添加的插入突变风险,但脱靶毒性需关注。

核心结论

  • HSC GT对PID前景广阔,但每种疾病需个体化策略,并需平衡插入突变和脱靶毒性风险。

研究设计与样本

  • 综述文章,检索范围未在摘要中报告。

主要发现

  • alloHSCT对许多PID可治愈,但存在移植物失败或GvHD导致的死亡和并发症风险。
  • 自体HSC GT可避免异基因移植并发症,纠正造血谱系遗传缺陷。
  • 首个获批HSC-GT产品针对ADA-SCID,已可用于临床。
  • 基因编辑技术有望规避病毒基因添加的相关问题。
  • HSC GT风险包括γ逆转录病毒基因添加的插入突变和基因编辑的脱靶毒性。

临床怎么用

  • 对于适合的PID患者,可考虑自体HSC GT作为alloHSCT的替代方案,以避免GvHD风险。
  • ADA-SCID患者已有获批的HSC-GT产品可用。
  • 应用基因编辑技术时需评估脱靶毒性风险。

局限性

  • 摘要未报告综述的检索范围和方法学细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary immunodeficiencies (PIDs) are a group of rare inherited disorders of the immune system. Many PIDs are devastating and require a definitive therapy to prevent progressive morbidity and premature mortality. Allogeneic haematopoietic stem cell transplantation (alloHSCT) is curative for many PIDs, and while advances have resulted in improved outcomes, the procedure still carries a risk of mortality and morbidity from graft failure or graft-versus-host disease (GvHD). Autologous haematopoietic stem cell gene therapy (HSC GT) has the potential to correct genetic defects across haematopoietic lineages without the complications of an allogeneic approach. HSC GT for PID has been in development for the last two decades and the first licensed HSC-GT product for adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) is now available. New gene editing technologies have the potential to circumvent some of the problems associated with viral gene-addition. HSC GT for PID shows great promise, but requires a unique approach for each disease and carries risks, notably insertional mutagenesis from gamma-retroviral gene addition approaches and possible off-target toxicities from gene-editing techniques. In this review, we discuss the development of HSC GT for PID and outline the current state of clinical development before discussing future developments in the field.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Fox TA, Booth C. Gene therapy for primary immunodeficiencies. Br J Haematol. 2020. PMID: 33336808. doi:10.1111/bjh.17269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。